WO2020252169A1 - Inhalateurs intelligents à commande biométrique - Google Patents

Inhalateurs intelligents à commande biométrique Download PDF

Info

Publication number
WO2020252169A1
WO2020252169A1 PCT/US2020/037242 US2020037242W WO2020252169A1 WO 2020252169 A1 WO2020252169 A1 WO 2020252169A1 US 2020037242 W US2020037242 W US 2020037242W WO 2020252169 A1 WO2020252169 A1 WO 2020252169A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhaler
drug
smart
biometric reader
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/037242
Other languages
English (en)
Inventor
Robert FISHEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alsar LP
Original Assignee
Alsar LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alsar LP filed Critical Alsar LP
Publication of WO2020252169A1 publication Critical patent/WO2020252169A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
    • A61B5/0006—ECG or EEG signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
    • A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Measuring devices for evaluating the respiratory organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/25—Bioelectric electrodes therefor
    • A61B5/279—Bioelectric electrodes therefor specially adapted for particular uses
    • A61B5/28—Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/346—Analysis of electrocardiograms
    • A61B5/349—Detecting specific parameters of the electrocardiograph cycle
    • A61B5/363—Detecting tachycardia or bradycardia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4094—Diagnosing or monitoring seizure diseases, e.g. epilepsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6887—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient mounted on external non-worn devices, e.g. non-medical devices
    • A61B5/6898—Portable consumer electronic devices, e.g. music players, telephones, tablet computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient; User input means
    • A61B5/7465—Arrangements for interactive communication between patient and care services, e.g. by using a telephone network
    • A61B5/747—Arrangements for interactive communication between patient and care services, e.g. by using a telephone network in case of emergency, i.e. alerting emergency services
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/0081—Locking means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02—Operational features
    • A61B2560/0204—Operational features of power management
    • A61B2560/0214—Operational features of power management of power generation or supply
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
    • A61B5/1112—Global tracking of patients, e.g. by using GPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient; User input means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/0083—Timers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/04—General characteristics of the apparatus implanted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/18—General characteristics of the apparatus with alarm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/27—General characteristics of the apparatus preventing use
    • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3317—Electromagnetic, inductive or dielectric measuring means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or Bluetooth®
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3592—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards
    • A61M2205/505—Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8206—Internal energy supply devices battery-operated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/01—Remote controllers for specific apparatus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/08—Other bio-electrical signals
    • A61M2230/10—Electroencephalographic signals
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Definitions

  • the invention relates to a smart inhaler controlled by biometric signals and methods thereof. Specifically, the invention relates to a device comprising a biometric signal reader (e.g., an electrocardiogram unit) and an inhaler unit for detecting and treating various diseases and conditions.
  • a biometric signal reader e.g., an electrocardiogram unit
  • an inhaler unit for detecting and treating various diseases and conditions.
  • SVT Supraventricular tachycardia
  • atrial fibrillation and atrial flutter are serious heart diseases.
  • SVT is due to a reentrant arrhythmia typically involving an extra electrical connection between the atria and ventricles and the normal electrical conduction system of the heart.
  • a circus movement of impulses causes reentry between the extra connection and the normal conduction system resulting in heart rates stuck around 180 - 200 BPM.
  • the typical way of terminating SVT is to give a drug that temporarily blocks conduction in the atrioventricular (AV) node which is part of the normal conduction system of the heart thus terminating this loop of tachycardia.
  • AV atrioventricular
  • Adenosine is typically administered in the emergency room for these types of patients, causing a brief period of blocks AV nodal conduction, and thus terminating this vicious circle.
  • One of the problems with current delivery devices includes reluctance to allow patients to self-administer a drug that can cause hypotension and thus a passing out spell without the patient knowing they are actually in SVT.
  • the current devices also lack smart features.
  • epiliepsy may be detected based on biometric signals from the brain measured by an electroencephalogram (“EEG”), and epliepsy may then be treated by a drug, such as Carbamazepine, Phenytoin, or Valproic acid.
  • EEG electroencephalogram
  • epliepsy may then be treated by a drug, such as Carbamazepine, Phenytoin, or Valproic acid.
  • the invention provides a device comprising: a biometric reader, capable of detecting an abnormal condition; and an inhaler unit capable of delivering a drug to an airway of a subject, wherein said biometric reader is operably linked to said inhaler unit, and wherein said inhaler unit delivers said drug to said airway in said subject in response to said biometric reader’ s detection of the abnormal condition in said subject.
  • the device comprises a first handgrip and a second handgrip, wherein each the first and second grips comprises an electrode of said biometric reader.
  • the device comprises an interlocking mechanism, said mechanism is capable of blocking or stopping the activation of the delivery of the drug by said inhaler unit until the detection of said abnormal condition by said biometric reader.
  • the biometric reader is an electrocardiogram (ECG) unit and the abnormal condition is a heart disease or condition, such as supraventricular tachycardia (SVT).
  • the drug is any suitable drug for treating SVT, for example, verapamil.
  • the biometric reader is an electroencephalogram (EEG) unit and the abnormal condition is a condition associated with epilepsy.
  • the drug is any suitable drug for treating epilepsy, for example, carbamazepine, phenytoin, or valproic acid.
  • the invention provides a method for treating abnormal conditions, such as a heart disease or heart condition or epilepsy in a subject in need thereof, the method comprising: providing the device of the invention described herein, detecting the abnormal condition with the aid of the device, and activating the device to deliver the drug to the subject, thereby treating the abnormal condition.
  • abnormal conditions such as a heart disease or heart condition or epilepsy
  • the invention provides a healthcare system comprising the device of the invention described.
  • Figure 1 A illustrates a perspective view of a smart oral inhaler device of the invention, according to one embodiment of the invention.
  • Figure IB illustrates a top view of a smart oral inhaler device of the invention, according to one embodiment of the invention.
  • Figure 1C illustrates a bottom view of a smart oral inhaler device of the invention, according to one embodiment of the invention.
  • Figure ID illustrates a cutaway view of a smart oral inhaler device of the invention, according to one embodiment of the invention.
  • Figure 2A illustrates a perspective view of a smart nasal inhaler device of the invention, according to one embodiment of the invention.
  • Figure 2B illustrates a top view of a smart nasal inhaler device of the invention, according to one embodiment of the invention.
  • Figure 2C illustrates a bottom view of a smart nasal inhaler device of the invention, according to one embodiment of the invention.
  • Figure 2D illustrates a cutaway view of a smart nasal inhaler device of the invention, according to one embodiment of the invention.
  • Figure 3A illustrates a smart system for detecting an abnormal condition, such as an abnormal heart rhythm, and delivering a drug to a patient, according to one embodiment of the invention.
  • Figure 3B illustrates a smart system for detecting an abnormal condition, such as an abnormal heart rhythm, and delivering a drug to a patient, according to another embodiment of the invention.
  • Figures 4A-4C illustrate side perspective views of a smart inhaler, according to embodiments of the invention.
  • Figures 5A and 5B illustrates a front view and a back view, respectively, of a smart remote controller for detecting an abnormal condition, according to embodiments of the invention.
  • Figure 5C illustrates an inside of the smart remote controller, according to embodiments of the invention.
  • Figure 5D illustrates a combined smart remote controller and inhaler, according to embodiments of the invention.
  • Figure 6 illustrates a smart system for detecting an abnormal condition and delivering a drug to a patient, according to one embodiment of the invention.
  • treatment or “therapy” (as well as different forms thereof) include preventative (e.g., prophylactic), curative or palliative treatment.
  • treating includes alleviating or reducing at least one adverse or negative effect or symptom of a condition, disease or disorder.
  • subject refers to an animal, for example a human, to whom treatment, including prophylactic treatment, with the pharmaceutical composition according to the present invention, is provided.
  • A“user” as referred to herein may also include an individual employing an aspect of the invention, such as a healthcare worker, computer operator, etc.
  • subject refers to human and non-human animals.
  • a “subject” herein is an animal of any species, preferably mammalian, most preferably human.
  • Conditions and disorders in a subject for which a particular drug or compound (e.g., verapamil) is said herein to be “indicated” are not restricted to conditions and disorders for which that drug or compound has been expressly approved by a regulatory authority, but also include other conditions and disorders known or reasonably believed by a physician to be amenable to treatment with that drug or compound.
  • a particular drug or compound e.g., verapamil
  • the invention provides a smart inhaler device that comprises onboard electrocardiogram (ECG) analysis to determine if the device should unlock an inhaled drug to be given to treat an underlying arrhythmia.
  • ECG electrocardiogram
  • the device includes two handgrips that can be configured to produce an internal lead 1 ECG for analysis; an interlock which prevents self-administration of an inhaled drug unless a certain arrhythmia is confirmed by onboard analysis; a cartridge type insertion port for the drug vial to be delivered; and/or a smart chip, and potentially a power source integrated into the drug vial and provided as a single prescription unit.
  • the smart chip can prevent excessive inhalations within a given time period for a given drug, as well as lock out the inhaler when the associated drug expires.
  • the device comprises a display informing or alerting the user that an appropriate arrythmia, such as SVT, has been confirmed, then instructing, by prompts, the user to self-administer the drug.
  • the prompts can be of any suitable type, such as, without limitation, verbal, other audible, visual, tactical, vibration, or any combination.
  • the device may include a potential for information to be wirelessly linked to a smart phone and/or real time monitoring center at a remote location.
  • the device comprises a memory chip or other memory to record information, such as, for example, but without limitation individual sessions.
  • the device comprises an integrated cell modem. [00037] Reference is made to FIGS.
  • the smart inhaler 100 may include a first grip 105, a body 101, a mouth piece 103, and a second grip 107.
  • An outside surface of the first grip 105 and an outside surface of the second grip 107 may include a first electrode 111 and a second electrode 113, respectively, which are part of a biometric reader (e.g., biometric reader unit 147 shown in FIG. ID).
  • the body 101 may include an indicator 109, an emergency button 115, and/or a plurality of sensors 117.
  • the smart inhaler 100 may include a biometric reader unit 147 (e.g., an electrocardiogram (“ECG”) unit or an electroencephalogram (“EEG”) unit), a pump 145, a lock 133, an analyzer/processor 135, a memory 137, a transceiver 139, a global positioning system (“GPS”) 141, a replaceable battery 159, and a database 143.
  • the pump 145 may include a sealed compartment 125 for medicine (e.g., a medication cartridge), a metering valve 127, a spring 129, and an opening 131.
  • the smart inhaler 100 is a consolidated smart inhaler having a replaceable battery or other power source, such as a rechargeable battery, and a medication cartridge.
  • At least one of the first grip 105 and the second grip 107 is movable towards each other when pressed by the user.
  • a top end of the metering valve 127 may be configured to temporarily penetrate the sealed compartment 125 causing pressurized medicine from the sealed compartment 125 to travel through the metering valve 127 and out through opening 131 so that the medicine may be delivered to the user through an opening in the mouthpiece 103.
  • the spring 129 may be configured to return the metering valve 127 to a position where the sealed compartment 125 isn’t penetrated by the metering valve 127 and, thus, is still a sealed compartment that is no longer in fluid communication with the opening 131.
  • the biometric reader unit 147 may be configured to measure a biometric signal (e.g., electrical activity of a heartbeat) of a user via the first electrode 111 and the second electrode 113 when the user grips the smart inhaler 100, for example by simultaneously positioning a thumb and one or more fingers on the first electrode 111 of the first grip 105 and the second electrode 113 of the second grip 107.
  • the biometric reader unit 147 may be located externally to the smart inhaler 100 and the transceiver 139 may be configured to transmit and/or receive signals from the smart inhaler 100.
  • the smart inhaler 100 is operable with a smart device, such as a smart phone, a smart watch, a tablet, or an implantable loop recorder, which communicates wired or wirelessly with the smart inhaler.
  • a smart device such as a smart phone, a smart watch, a tablet, or an implantable loop recorder, which communicates wired or wirelessly with the smart inhaler.
  • the biometric reader unit 147 and/or the electrodes 111 and 113 may be part of the smart device, an attachment to the smart device and/or a part of protective cover of the smart device (e.g., a smart phone case).
  • the analyzer/processor 135 may be configured to detect or sense values determined by the biometric reader 147 while the user grips the smart inhaler 100 by the first grip 105 and the second grip 107.
  • the analyzer/processor 135 may be configured to determine the presence or absence of an abnormal brain or body condition, such as an abnormal heart rhythm, of the user by determining if the biometric reader 147 detects a predetermined biometric value or a predetermined change in a biometric value.
  • the lock 133 may be configured to block, stop, or otherwise prevent activation or delivery of a drug located in compartment 125 until the biometric reader 147/processor 135 detects the abnormal body or brain condition, such as an abnormal heart rhythm, of the user via the first electrode 111 and second electrode 113.
  • the lock 133 may be configured to prevent the first grip 105 and second grip 107 from being moved, and thus, prevent the metering valve 127 from penetrating the sealed compartment 125.
  • the lock 133 may be configured to prevent more than a predetermined number of inhalations (e.g., activations or deliveries of the drug located in compartment 125) within a predetermined period of time (e.g., from when the biometric reader 147/ processor 135 detects the abnormal heart rhythm), such as to prevent excessive dosing or overdosing.
  • a predetermined number of inhalations e.g., activations or deliveries of the drug located in compartment 125
  • a predetermined period of time e.g., from when the biometric reader 147/ processor 135 detects the abnormal heart rhythm
  • the lock 133 may be an automatic lock which automatically unlocks and allows for the delivery of said drug by said inhaler when said abnormal condition is detected by said biometric reader 147 and/or said processor 135.
  • the lock 133 is a manual lock that requires user input to unlock and allow for the delivery of said drug by said inhaler when said abnormal condition is detected by said biometric reader 147 and/or said processor 135.
  • the indicator 109 may be a speaker, a light, and/or a vibrating motor configured to indicate to the user, by producing a sound, a light, or a vibration, when said abnormal condition is detected by said biometric reader 147 and/or said processor 135.
  • the indicator 109 may be configured to notify the user to utilize the smart inhaler 100 to check for an abnormal heart rhythm (e.g., a predetermined amount of times during a day).
  • the processor 135 may be configured to utilize the transceiver 141 to automatically call or otherwise message a third party (e.g., a first responder) if the user/patient has failed to utilize the smart inhaler 100 to check for an abnormal condition within a predetermined time from a notification to check for an abnormal condition.
  • the analyzer/processor 135 may be configured to warn a user via the indicator 109 or via a message sent to a user’s smart device (e.g., smart phone, smart watch, tablet, computer, etc.) when medication inserted into the smart inhaler 100 has or is about to expire.
  • the warning may be a line of text displayed on a screen of the indicator 109 or in an email, text message, or any other message that can be automatically sent.
  • the analyzer/processor 135 may be configured to have the lock 133 block, stop, or otherwise prevent activation or delivery of a drug located in compartment 125 until the expired or expiring medication is exchanged.
  • the analyzer/processor 135 may be configured to allow the inhaler unit to deliver said medication to said airway in said subject in response to said biometric reader’s detection of said abnormal condition in said subject, if the medication has not expired or is not about to expire.
  • the memory 137 may include cache memory, long term memory such as a hard drive, and/or external memory, for example, including random access memory (RAM), read only memory (ROM), dynamic RAM (DRAM), synchronous DRAM (SD-RAM), a double data rate (DDR) memory chip, flash memory, volatile memory, non-volatile memory, cache memory, buffer, short term memory unit, long term memory unit, magnetic tape, or other suitable memory units or storage units.
  • Memory 137 may store instructions and data to execute embodiments of the described methods, steps and functionality (e.g., in long term memory, such as a hard drive).
  • Memory may be or may include a plurality of, possibly different memory units. Memory may also store one or more software program modules or software instructions for execution by a processor as described herein.
  • the database 143 may be configured to store data produced from the first electrode 111 and second electrode 113, the biometric reader 147 and/or the processor 135.
  • the database may be configured to store drug delivery data (e.g., when and/or how many times the metering valve 127 has penetrated the sealed compartment 125).
  • the plurality of sensors 117 may be configured to determine whether the patient/user is in a stable condition. Sensors may include devices to monitor patients and to determine the stability of patients. Such sensors or devices are well known in the art.
  • FIGS. 2A, 2B, and 2C are a perspective view, top view, and a bottom view of a smart nasal inhaler 200, respectively.
  • the smart nasal inhaler 200 may include a nose piece 203, a first grip 205, a body 201, and a second grip 207.
  • An outside surface of the first grip 205 and an outside surface of the second grip 207 may include a first electrode 211 and a second electrode 213, respectively, according to embodiments of the invention.
  • the body 201 may include an indicator 209, an emergency button 215, and/or a plurality of sensors 217.
  • the smart nasal inhaler 200 may include biometric reader unit 247 (e.g., an electrocardiogram (“ECG”) unit or an electroencephalogram (“EEG”) unit), a pump 245, a lock 233, an analyzer/processor 235, a memory 237, a transceiver 239, a global positioning system (“GPS”) 241, a replaceable battery 259, and a database 243.
  • the pump 245 may include a sealed compartment 225 for medicine (e.g., a medication cartridge), a metering valve 227, and a spring 229.
  • the smart nasal inhaler 200 is a consolidated smart inhaler having a replaceable battery and a medication cartridge.
  • At least one of the first grip 205 and the second grip 207 is movable towards each other when pressed by the user.
  • a top end of the metering valve 227 may be configured to temporarily penetrate the sealed compartment 225 causing pressurized medicine from the sealed compartment 225 to travel through the metering valve 227 and out through an opening in the nose piece 203 so that the medicine may be delivered to the user.
  • the spring 229 may be configured to return the metering valve 227 to a position where the sealed compartment 225 isn’t penetrated by the metering valve 227 and, thus, is still a sealed compartment that is no longer in fluid communication with the opening 231.
  • the biometric reader 247 may be configured to measure biometric signals, such as electrical activity of a heartbeat, of a user via the first electrode 211 and the second electrode 213 when the user grips the smart nasal inhaler 200, for example by simultaneously positioning a thumb and one or more fingers on the first electrode 111 of the first grip 205 and the second electrode 213 of the second grip 207.
  • the biometric reader 247 may be located externally to the smart inhaler 200 and the transceiver 239 may be configured to transmit and/or receive signals from the smart nasal inhaler 200.
  • the smart nasal inhaler 200 is operable with a smart device, such as a smart phone, a smart watch, a tablet, or an implantable loop recorder, which communicates wired or wirelessly with the smart inhaler.
  • a smart device such as a smart phone, a smart watch, a tablet, or an implantable loop recorder, which communicates wired or wirelessly with the smart inhaler.
  • the biometric reader unit 247 and/or the electrodes 211 and 213 may be part of the smart device, an attachment to the smart device, and/or a part of protective cover of the smart device (e.g., a smart phone case).
  • the analyzer/processor 235 may be configured to detect or sense values determined by the biometric reader 247 while the user grips the smart nasal inhaler 200 by the first grip 205 and the second grip 207.
  • the analyzer/processor 235 may be configured to determine the presence or absence of an abnormal brain or body condition, such as an abnormal heart rhythm, of the user by determining if the biometric reader 147 detects a predetermined biometric value or a predetermined change in a biometric value.
  • the lock 233 may be configured to block, stop, or otherwise prevent activation or delivery of a drug located in compartment 225 until the biometric reader 247/processor 235 detects the abnormal condition (e.g., abnormal heart rhythm) of the user via the first electrode 211 and second electrode 213.
  • the lock 233 may be configured to prevent the first grip 205 and second grip 207 from being moved, and thus, prevent the metering valve 227 from penetrating the sealed compartment 225.
  • the lock 233 may be configured to prevent more than a predetermined number of inhalations (e.g., activations or deliveries of the drug located in compartment 225) within a predetermined period of time (e.g., from when the biometric reader 247/ processor 235 detects the abnormal heart rhythm), such as to prevent excessive dosing or overdosing.
  • a predetermined number of inhalations e.g., activations or deliveries of the drug located in compartment 225
  • a predetermined period of time e.g., from when the biometric reader 247/ processor 235 detects the abnormal heart rhythm
  • the lock 233 may be an automatic lock which automatically unlocks and allows for the delivery of said drug by said inhaler when said abnormal condition is detected by said biometric reader 247 and/or said processor 235.
  • the lock 233 is a manual lock that requires user input to unlock and allow for the delivery of said drug by said inhaler when said abnormal condition is detected by said biometric reader 247 and/or said processor 235.
  • the indicator 209 may be a speaker, a light, and/or a vibrating motor configured to indicate to the user, by producing a sound, a light, or a vibration, when said abnormal condition is detected by said biometric reader 247 and/or said processor 235.
  • the indicator 209 may be configured to notify the user to utilize the smart nasal inhaler 200 to check for an abnormal condition (e.g., a predetermined amount of times during a day).
  • the processor 235 may be configured to utilize the transceiver 241 to automatically call or otherwise message a third party (e.g., a first responder) if the user/patient has failed to utilize the smart nasal inhaler 200 to check for an abnormal brain or body condition within a predetermined time from an notification to check for an abnormal brain or body condition.
  • the analyzer/processor 235 may be configured to warn a user via the indicator 209 or via a message sent to a user’s smart device (e.g., smart phone, smart watch, tablet, computer, etc.) when medication inserted into the smart nasal inhaler 200 has or is about to expire.
  • the warning may be a line of text displayed on a screen of the indicator 209 or in an email, text message, or any other message that can be automatically sent.
  • the analyzer/processor 235 may be configured to have the lock 233 block, stop, or otherwise prevent activation or delivery of a drug located in compartment 225 until the expired or expiring medication is exchanged.
  • the analyzer/processor 235 may be configured to allow the inhaler unit to deliver said medication to said airway in said subject in response to said biometric reader’s detection of said abnormal condition in said subject, if the medication has not expired or is not about to expire.
  • the memory 237 may include cache memory, long term memory such as a hard drive, and/or external memory, for example, including random access memory (RAM), read only memory (ROM), dynamic RAM (DRAM), synchronous DRAM (SD-RAM), a double data rate (DDR) memory chip, flash memory, volatile memory, non-volatile memory, cache memory, buffer, short term memory unit, long term memory unit, magnetic tape, or other suitable memory units or storage units.
  • Memory 237 may store instructions and data to execute embodiments of the described methods, steps and functionality (e.g., in long term memory, such as a hard drive).
  • Memory may be or may include a plurality of, possibly different memory units. Memory may also store one or more software program modules or software instructions for execution by a processor as described herein.
  • the database 243 may be configured to store data produced from the first electrode 211 and second electrode 213, the biometric reader 247 and/or the processor 235.
  • the database may be configured to store drug delivery data (e.g., when and/or how many times the metering valve 227 has penetrated the sealed compartment 225).
  • the emergency button 215 may be configured to utilize the transceiver 241 and/or processor 235 to automatically initiate a call or otherwise message a third-party (e.g., a first responder) when pressed by the user.
  • a third-party e.g., a first responder
  • the GPS 241 may be configured to determine the location of the smart inhaler 201 to assist a third-party (e.g., a first responder) to determine the location of the patient/user.
  • a third-party e.g., a first responder
  • the plurality of sensors 217 may be configured to determine whether the patient/user is in a stable condition.
  • sensors may include devices to monitor patients and to determine the stability of patients. Such sensors or devices are well known in the art.
  • FIGS. 3A and 3B illustrates smart systems for detecting an abnormal brain or body condition, such as an abnormal heart rhythm, and delivering a drug to a user/patient via the smart inhaler 100 and smart nasal spray 200, respectively, according to embodiments of the invention.
  • the smart inhaler 100 and smart nasal spray 200 can communicate with a remote system 350 (e.g., a processor, tablet, and/or a smart phone) via a network 325.
  • a remote system 350 e.g., a processor, tablet, and/or a smart phone
  • the transceivers 141 and 241 may be or comprise a Bluetooth linker configured to facilitate the remote system to remotely download or store recorded data from the first electrodes 111 and 211 and second electrodes 113 and 213, the biometric readers 147 and 247 and/or the processors 135 and 235 of the smart inhaler 100 and smart nasal inhaler 200, respectively.
  • the remote system 350 may be the user/patient’s and/or a healthcare provider’s computer, tablet, smart watch, smart phone, or any other smart device.
  • the emergency buttons 115 and 215 may be configured to utilize the transceivers 141 and 241 and/or processor 135 and 235 to automatically initiate a call or otherwise message a third-party (e.g., a first responder) when pressed by the user.
  • a third-party e.g., a first responder
  • the GPSs 141 and 241 may be configured to determine the location of the smart inhaler 101 to assist a third-party (e.g., a first responder) to determine the location of the patient/user.
  • a third-party e.g., a first responder
  • FIGS. 4A-C are side perspective views of a smart oral/nasal inhaler, according to embodiments of the invention.
  • the smart inhaler may include a first grip 405 (e.g., first grip 105 of FIGS. 1A-D), a body 401 (e.g., body 101 from FIGS. 1A-D), a mouth piece 403 (e.g., mouth piece 103 from FIGS. 1A-D), and a second grip 407 (e.g., second grip 107 from FIGS. 1A-D).
  • An outside surface of the first grip 405 and an outside surface of the second grip 407 may include a first electrode 411 (e.g., first electrode 111 of FIGS. 1A-D) and a second electrode 413 (e.g., second electrode 113 of FIGS. 1A-D), respectively.
  • the body 401 may include an indicator 409 (e.g., indicator 109 of FIGS. 1A-D), an emergency button 415 (e.g., emergency button 115 of FIGS. 1A-D), and a plurality of sensors 417 (e.g., plurality of sensors 117 of FIGS. 1A-D).
  • an indicator 409 e.g., indicator 109 of FIGS. 1A-D
  • an emergency button 415 e.g., emergency button 115 of FIGS. 1A-D
  • a plurality of sensors 417 e.g., plurality of sensors 117 of FIGS. 1A-D
  • FIG. 4A which is an exploded view of the smart oral/nasal inhaler
  • a separate nose piece 452 which may be configured to be attachable to the mouthpiece 403 to convert from a smart inhaler mode to a smart nasal spray mode as shown in FIGS. 4B-C.
  • the nose piece 452 may include a third grip 476 having a third electrode 478 located on a surface of the third grip 476 which faces away from the body 401 of the smart oral/nasal inhaler.
  • the internal components of the smart oral/nasal inhaler may be the same as those described in FIGS. ID and 2D (e.g., includes the biometric reader 147, the pump 145, the lock 133, the analyzer/processor 135, the memory 137, the transceiver 139, the GPS 141, and the database 143).
  • the ECG 147 may be configured to measure a biometric signal, such as electrical activity of a heartbeat, of a user via the first electrode 411 and either the second electrode 413 or the third electrode 478 when the user grips the smart inhaler 100, for example by simultaneously positioning a thumb and one or more fingers on the first electrode 411 of the first grip 405 and either the second electrode 413 of the second grip 407 or the third electrode 478 or the third grip 476.
  • a biometric signal such as electrical activity of a heartbeat
  • any suitable inhaler unit known to one of skilled in the art can be used in the device of the invention.
  • the inhaler unit is a dry-powder inhaler.
  • the inhaler unit is a metered dose inhaler.
  • FIGS 5A and 5B are a front view and a back view, respectively, of a smart remote controller for detecting an abnormal condition, such as an abnormal heart rhythm, according to embodiments of the invention.
  • the smart remote controller may be separate from the smart inhaler.
  • the smart remote controller may be a video game controller, such as an Xbox controller, a remote control for a television, or any other remote-controller device, having any other configuration suitable to perform its intended functions as described herein.
  • An outside surface of the smart remote controller may include two or more electrodes 511-514, 590, and 592, which are part of a biometric reader (e.g., biometric reader 547 shown in FIG. 5C).
  • the smart remote controller may include an indicator 509 (e.g., indicator 109 of FIGS. 1A-D), a screen 591, an emergency button 515 (e.g., emergency button 115 of FIGS. 1A-D), and a plurality of sensors 517 (e.g., plurality of sensors 117 of FIGS. 1A-D).
  • a first right electrode 511 may be located on a button 550 (e.g., a right directional control button) located on a right side of the front surface of the smart remote controller.
  • a first left electrode 513 may be located on a button 552 (e.g., a left directional control button) located on a left side of the front surface of the smart remote controller.
  • a second right electrode 512 and a second left electrode 514 may be located on a right and left side, respectively, of the back of the smart remote controller.
  • a third right electrode 590 may be located on a button located on a right top side of the smart controller 500.
  • a third left electrode 592 may be located on a button located on a left top side of the smart controller 500.
  • the screen 591 may be a liquid crystal display (“LCD”) configured to display a warning, such as a line of text, to warn a user when medication inserted into an inhaler portion of the smart remote controller has or is about to expire, as discussed above.
  • the screen 591 and/or indicator 509 may be configured to indicate if a medical condition requiring inhalation has been detected.
  • the smart remote control may include a biometric reader 547, such as an electrocardiogram (“ECG”) unit, (e.g., biometric reader unit 147 of FIG. ID), an analyzer/processor 535 (e.g., the processor 135 of FIG. ID), a transceiver 539 (e.g., the transceiver 139 of FIG. ID), a global positioning system (“GPS”) 541 (e.g., the GPS 141 of FIG. ID), and a database 543 (e.g., the database 143 of FIG. ID).
  • ECG electrocardiogram
  • GPS global positioning system
  • the biometric reader unit 547 may be configured to measure a biometric signal (e.g., electrical activity of a heartbeat) of a user via a first right electrode 511 and a first left electrode 513 when the user grips the smart remote control, for example, by simultaneously positioning a thumb, on each of the first right electrode 511 and the first left electrode 513.
  • the biometric reader unit 547 may be configured to measure a biometric signal of the user via the first right electrode 511 and the second right electrode 512 when the user grips the smart remote control, for example, by simultaneously position a thumb on the first right electrode 511 and a finger, such as the pointer finger, on the second right electrode 512.
  • the biometric reader unit 547 may be configured to measure a biometric signal of the user via the first left electrode 513 and the second left electrode 514 when the user grips the smart remote control, for example, by simultaneously position a thumb on the first left electrode 531 and a finger, such as the pointer finger, on the second left electrode 514.
  • the biometric reader unit 547 may be configured to measure a biometric signal (e.g., electrical activity of a heartbeat) of a user via a third right electrode 590 and the third left electrode 592 when the user grips the smart remote control, for example, by simultaneously positioning a finger, on each of the third right electrode 590 and the third left electrode 592.
  • a biometric signal e.g., electrical activity of a heartbeat
  • the smart remote controller may have two handles 566 and 566’, which each have an electrically active sensor, such as an electrode, configured to measure a biometric signal (e.g., electrical activity of a heartbeat) of a user when the user grips the remote controller by both handles 566 and 566’.
  • the smart remote controller may have an electrode on a front side and a back side of the smart remote controller, such that when the smart remote controller is configured to be operated by gripping it with both hands, the biometric reader unit 547 can measure a biometric signal (e.g., electrical activity of a heartbeat) of a user which grips the front and back side simultaneously.
  • the smart inhaler is powered on by gripping both the right and left handgrips that have integrated electrodes and pressure sensors. Once powered on, the smart inhaler then can also sense electrical activity of the heart via the left and right handgrip obtaining the electrical equivalent of ECG, which then can be used for internal analysis of the electrical activity of the heart.
  • the biometric reader unit 547 may be an accessory attachment.
  • the smart remote controller may be configured to have more than one electrode and/or an ECG unit operably attached to the smart remote controller.
  • the smart remote controller is operable as a smart device or is a smart device, such as a smart phone, a smart watch, a tablet, or an implantable loop recorder, which communicates wired or wirelessly with the smart inhaler.
  • the biometric reader unit 547 and/or the more than one electrode may be part of the smart device, an attachment to the smart device, and/or a part of protective cover of the smart device (e.g., a smart phone case).
  • the biometric reader unit 547 may be located externally to the smart controller and the transceiver 539 may be configured to transmit and/or receive signals from the smart inhaler.
  • the analyzer/processor 535 may be configured to detect or sense values determined by the biometric reader 547 while the user grips the smart remote controller while contacting at least two of the electrodes 511-514, 590, and 592.
  • the analyzer/processor 535 may be configured to determine the presence or absence of an abnormal brain or body condition, such as an abnormal heart rhythm, of the user by determining if the biometric reader 547 detects a predetermined biometric value or a predetermined change in a biometric value.
  • the indicator 509 may be a speaker, a light, and/or a vibrating motor or any other suitable indicator configured to indicate to the user, by producing a sound, a light, or a vibration, or other indication, when said abnormal condition is detected by said biometric reader 547 and/or said processor 535.
  • the indicator 509 may be configured to notify the user to utilize the smart controller to check for an abnormal heart rhythm (e.g., a predetermined amount of times during a day).
  • the processor 535 may be configured to utilize the transceiver 541 to automatically call or otherwise message a third party (e.g., a first responder) if the user/patient has failed to utilize the smart remote controller to check for an abnormal condition within a predetermined time from a notification to check for an abnormal condition.
  • a third party e.g., a first responder
  • the memory 537 may include cache memory, long term memory such as a hard drive, and/or external memory, for example, including random access memory (RAM), read only memory (ROM), dynamic RAM (DRAM), synchronous DRAM (SD-RAM), a double data rate (DDR) memory chip, flash memory, volatile memory, non-volatile memory, cache memory, buffer, short term memory unit, long term memory unit, magnetic tape, or other suitable memory units or storage units.
  • Memory 537 may store instructions and data to execute embodiments of the described methods, steps and functionality (e.g., in long term memory, such as a hard drive).
  • Memory may be or may include a plurality of, possibly different memory units. Memory may also store one or more software program modules or software instructions for execution by a processor as described herein.
  • the database 543 may be configured to store data produced from the electrodes 511- 514, 590, and 592, the biometric reader 547 and/or the processor 535.
  • the database may be configured to store drug delivery data.
  • the plurality of sensors 517 may be configured, without limitation, to determine whether the patient/user is in a stable condition. Sensors 517 may include devices to monitor patients and to determine the stability of patients. Such sensors or devices are well known in the art.
  • the smart remote controller 500 comprises an inhaler 580, as can be seen in FIG. 5D.
  • the inhaler 580 may include a mouthpiece 503 (e.g., the mouthpiece 103 of FIG. 1 A and ID), a pump (e.g., the pump 145 of FIG. ID), and a lock (e.g., lock 133 of FIG. ID).
  • the pump may include a sealed compartment (e.g., sealed compartment 125 of FIG.
  • the inhaler 580 may include a processor (not shown) configured to, based on the biometric reader 547 detecting a predetermined value or predetermined change in value, unlock the lock and cause a top end of the metering valve to temporarily penetrate the sealed compartment causing pressurized medicine from the sealed compartment to travel through the metering valve and out through opening so that the medicine may be delivered to the user through an opening in the mouthpiece 503.
  • the spring may be configured to return the metering valve to a position where the sealed compartment isn’t penetrated by the metering valve and, thus, is still a sealed compartment that is no longer in fluid communication with the opening.
  • at least one button e.g., the two buttons on which electrodes 590 and 592 are located
  • the remote controller 500 must be pressed to cause a top end of the metering valve to temporarily penetrate the sealed compartment.
  • the screen 591 and/or indicator 509 may be configured to indicate if the lock of the inhaler 580 is unlocked, such that the inhaler 580 is able to deliver said drug, as described above.
  • FIG. 6 illustrates a smart system for detecting an abnormal condition, such as an abnormal heart rhythm, and delivering a drug to a patient, according to one embodiment of the invention.
  • the smart system may include a smart remote controller 600 (e.g., smart remote controller 500 of FIGS. 5A-C) and a smart inhaler 675.
  • the smart inhaler 675 may include a mouth piece (e.g., mouth piece 103 of FIGS. 1A and ID), a biometric reader unit (e.g., the biometric reader unit 147 of FIG. ID), such as an electrocardiogram (“ECG”) unit, a pump (e.g., pump 145 of FIG. ID), a lock (e.g., lock 133 of FIG.
  • ECG electrocardiogram
  • the pump may include a sealed compartment (e.g., sealed compartment 125 of FIG. ID) for medicine, a metering valve (e.g., metering vale 127 of FIG. ID), a spring (e.g., spring 129 of FIG. ID), and an opening (e.g., opening 131 of FIG.
  • a sealed compartment e.g., sealed compartment 125 of FIG. ID
  • a metering valve e.g., metering vale 127 of FIG. ID
  • a spring e.g., spring 129 of FIG. ID
  • an opening e.g., opening 131 of FIG.
  • the smart remote controller 600, smart inhaler 675, and a remote system 650 may communicate via a network 625.
  • the smart remote controller 600 and smart inhaler 675 may directly communicate via a wire or wirelessly.
  • the biometric reader unit 547 of the smart remote control 600 or the biometric reader of the smart inhaler may be configured to measure a biometric signal (e.g., electrical activity of a heartbeat) of a user via a first right electrode 511 and a first left electrode 513 when the user grips the smart remote control, for example, by simultaneously positioning a thumb, on each of the first right electrode 511 and the first left electrode 513.
  • the biometric reader unit 547 may be configured to measure a biometric signal of the user via the first right electrode 511 and the second right electrode 512 when the user grips the smart remote control, for example, by simultaneously position a thumb on the first right electrode 511 and a finger, such as the pointer finger, on the second right electrode 512.
  • the biometric reader unit 547 may be configured to measure a biometric signal of the user via the first left electrode 513 and the second left electrode 514 when the user grips the smart remote control, for example, by simultaneously position a thumb on the first left electrode 531 and a finger, such as the pointer finger, on the second left electrode 514.
  • the biometric reader unit 547 or the biometric reader of the smart inhaler may be configured to measure a biometric signal (e.g., electrical activity of a heartbeat) of a user via a third right electrode 590 and the third left electrode 592 when the user grips the smart remote control, for example, by simultaneously positioning a finger, on each of the third right electrode 590 and the third left electrode 592.
  • a biometric signal e.g., electrical activity of a heartbeat
  • the transceiver 541 of the smart remote controller and/or the transceiver of the smart inhaler may be or comprise a Bluetooth linker configured to facilitate the remote system to remotely download or store recorded data from the electrodes 511-514, 590, and 592, the biometric reader 547 and/or the biometric reader of the smart inhaler 675 and/or the processors 535 of the smart remote control and/or the processor of the smart inhaler 675.
  • the remote system 550 may be the user/patient’s and/or a healthcare provider’s computer, tablet, smart phone, smart watch, or any other smart device.
  • the lock of the smart inhaler 675 may be configured to block, stop, or otherwise prevent activation or delivery of a drug located in the sealed compartment of the smart inhaler 675 until the biometric reader 547/processor 535 of the smart remote controller 600 or the biometric reader/processor of the smart inhaler 675 detects the abnormal body or brain condition, such as an abnormal heart rhythm, of the user via at least two of electrodes 511- 514, 590, and 592.
  • the lock may be configured to prevent a first grip (e.g., first grip 105 of FIG. 1 A) and second grip (e.g., second grip 107 of FIG.
  • the lock may be configured to prevent more than a predetermined number of inhalations (e.g., activations or deliveries of the drug located in compartment) within a predetermined period of time (e.g., from when the biometric reader 547/processor 535 of the smart remote controller 600 or the biometric reader/processor of the smart inhaler 675 detects the abnormal heart rhythm), such as to prevent excessive dosing or overdosing.
  • a predetermined number of inhalations e.g., activations or deliveries of the drug located in compartment
  • a predetermined period of time e.g., from when the biometric reader 547/processor 535 of the smart remote controller 600 or the biometric reader/processor of the smart inhaler 675 detects the abnormal heart rhythm
  • the lock may be an automatic lock which automatically unlocks and allows for the delivery of said drug by said inhaler when said abnormal condition is detected by the biometric reader 547/processor 535 of the smart remote controller 600 or the biometric reader/processor of the smart inhaler 675.
  • the lock is a manual lock that requires user input to unlock and allow for the delivery of said drug by said inhaler when said abnormal condition is detected by the biometric reader 547/processor 535 of the smart remote controller 600 or the biometric reader/processor of the smart inhaler 675.
  • the biometric reader 147, 247, or 547 may be configured to send the measured biometric value(s) to the remote system 350 or 650 and a physician may control whether to unlock the lock (e.g., lock 133 or 233) of the inhaler (e.g., inhaler 100, 200, 580, or 675), how much medicine to deliver, and/or, if there is more than one medicine included in the inhaler, which medicine to deliver.
  • the lock e.g., lock 133 or 233
  • the inhaler e.g., inhaler 100, 200, 580, or 675
  • a smart inhaler having a controller/processor that is in communication with a smart device, such as a smart phone, a smart watch, a tablet, or a laptop.
  • the smart device may have an attachment that includes more than one sensor, such as a pair of electrodes, configured to measure biometric signal (e.g., electrical activity of a heartbeat) of a user via the more than one sensor when the user touches the more than one sensor at the same time.
  • biometric signal e.g., electrical activity of a heartbeat
  • the attachment with more than one sensor may utilize the smart device to send the biometric signal to the smart inhaler’s controller/processor so that the controller/processor can determine whether or not to allow the smart inhaler to deliver medicine to the patient, for example, if an irregular brain or body condition, such as an irregular heart condition, is detected by the more than one sensors.
  • a consolidated smart unit which includes a biometric reader capable of detecting an abnormal brain or body condition based on biometric signals; a medication cartridge; an inhaler unit capable of delivering medication from the medication cartridge to an airway of a subject, wherein said biometric reader is operably linked to said inhaler unit, a replaceable battery; an interlock configured to block or stop the inhaler unit from delivering said medication by said inhaler unit until the detection of said abnormal brain or body condition by said biometric reader and a processor.
  • the user of the device of the invention is a human patient. In other embodiments, the user of the device of the invention is a healthcare professional.
  • any suitable drug known to one of skilled in the art can used in the device of the invention.
  • the drug is verapamil.
  • the drug is a flecainide.
  • the drug is a beta blocker drug.
  • the drug is a calcium channel blocker drug.
  • the drug is a digitalis.
  • the drug is a combination of a plurality of drugs described herein. Any drug suitable for inhalation can be delivered by devices in accordance with embodiments described herein.
  • Verapamil is a well known drug and fully described in U.S. Patents 10,144,704, 10,144,703, 9,950,995, 7,803,962, 5,955,500, 5,932,246, and 4,753,802, all of which are incorporated by reference herein in their entirety.
  • Flecainide is well known and fully described in U.S. Patents 9,750,734, 7,196,197, 6,599,922, 6,593,486, 6,538,138, and 6,316,627, and U.S. Patent Application Publications 20190008844, 20180028519, 20160158213, 20100184990, 20050059825, 20040220409, 20030032835, and 20020133013, all of which are incorporated by reference herein in their entirety.
  • Beta blockers also referred as b-blockers or beta blocker drugs
  • b-blockers or beta blocker drugs are a class of medications that are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack (myocardial infarction) after a first heart attack (secondary prevention). They are also widely used to treat high blood pressure (hypertension).
  • Beta blockers are competitive antagonists that block the receptor sites for the endogenous catecholamines epinephrine (adrenaline) and norepinephrine (noradrenaline) on adrenergic beta receptors, of the sympathetic nervous system.
  • Some block activation of all types of b-adrenergic receptors and others are selective for one of the three known types of beta receptors, designated b 1 , b 2 and b 3 receptors.
  • b 1 -adrenergic receptors are located mainly in the heart and in the kidneys.
  • b 2 -adrenergic receptors are located mainly in the lungs, gastrointestinal tract, liver, uterus, vascular smooth muscle, and skeletal muscle.
  • b 3 -adrenergic receptors are located in fat cells.
  • the beta blocker drug of the invention is a non-specific or non- selective beta blocker drug.
  • the beta blocker drug of the invention is a specific or selective beta blocker drug.
  • the beta blocker drug of the invention specifically or selectively blocks the activation of b 1 receptor.
  • the beta blocker drug of the invention specifically or selectively blocks the activation of b 2 receptor. In yet another example, the beta blocker drug of the invention specifically or selectively blocks the activation of b 3 receptor.
  • non-specific or non-selective beta blocker drug examples include, for example, but not limited to propranolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol, and timolol.
  • Examples of b 1 -selective or b 1 -specific beta blockers include, for example, but not limited to, acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, metoprolol, nebivolol, and esmolol.
  • b 1 -selective or b 1 -specific beta blockers are also known as cardioselective beta blockers.
  • the beta blocker drug is a b1-selective or b 1 -specific beta blocker.
  • Examples of b 2 -selective or b 2 -specific beta blockers include, for example, but not limited to, butaxamine and ICI-118,551.
  • Examples of b 3 -selective or b3-specific beta blockers include, for example, but not limited to, SR 59230A.
  • the beta blocker drug is a b 1 selective antagonist and b 3 agonist agent.
  • b 1 selective antagonist and b 3 agonist agent includes, but not limited to, nebivolol.
  • beta blocker drug examples include, but not limited to, bisoprolol, metoprolol, nadolol, betaxolol, bisoprolol, esmolol, alprenolol, bucindolol, levobunolol, medroxalol, mepindolol, metipranolol, propafenone (propafenone is a sodium channel blocking drug that also is a beta-adrenergic receptor antagonist), propranolol, sotalol, and timolol.
  • calcium channel blockers are dihydropyridine (DHP) calcium channel blockers.
  • DHP calcium channel blockers include, for example, but not limited to, amlodipine (Norvasc), aranidipine (Sapresta), azelnidipine (Calblock), barnidipine (HypoCa), benidipine (Coniel), cilnidipine (Atelec, Cinalong, Siscard), clevidipine (Cleviprex), efonidipine (Landel), felodipine (Plendil), isradipine (DynaCirc, Prescal), lacidipine (Motens, Lacipil), lercanidipine (Zanidip), manidipine (Calslot, Madipine), Nicardipine (Cardene, Carden SR), nifedipine (Procardia, Adalat), nilvadipine (Nivad
  • calcium channel blockers are non-dihydropyridine calcium channel blockers.
  • non-dihydropyridine calcium channel blockers include, for example, but not limited to, phenylalkylamine and benzothiazepine.
  • phenylalkylamine include, for example, but not limited to verapamil (Calan, Isoptin), fendiline, and gallopamil.
  • benzothiazepine include, for example, but not limited to, diltiazem (Cardizem).
  • calcium channel blockers are nonselective, which include, for example, but not limited to mibefradil, bepridil, flunarizine, fluspirilene, and fendiline.
  • calcium channel blockers include, for example, but not limited to, Ziconotide peptide and Gabapentinoids, such as gabapentin and pregabalin.
  • calcium channel blockers are, for example, dihydropyridines (e.g. amlodipine), benzothiapines (e.g. diltiazem), and phenylalkylamines (e.g. verapamil), felodipine, nifedipine.
  • dihydropyridines e.g. amlodipine
  • benzothiapines e.g. diltiazem
  • phenylalkylamines e.g. verapamil
  • felodipine nifedipine.
  • the drug of the invention is a digitalis, which is well known and fully described in, for example, U.S. Patents 6,465,463; 5,545,623; 5,153,178; 4,436,828; 4,282,151; 4,133,949; and 3,997,525 and U.S. Patent Application Publications 20060205679; 20160206641; 20090209504; 20050026849; 20040082521; and 20040023967, all of which are incorporated by reference herein in their entirety.
  • the digitalis is a digitalis glycoside.
  • a digitalis glycoside include, for example, but not limited to oleandrin, neriifolin, odoroside A and H, ouabain (G-strophantin), cymarin, sarmentocymarin, periplocymarin, K-strophantin, thevetin A, cerberin, peruvoside, thevetosin, thevetin B, tanghinin, deacetyltanghinin, echujin, hongheloside G, honghelin, periplocin, strophantidol, nigrescin, uzarin, calotropin, cheiroside A, cheirotoxin, euonoside, euobioside, euomonoside, lancetoxin A and B, kalanchoside, bryotoxin A-C, bryophyllin B, cotiledo
  • the digitalis glycoside is digitoxin or digoxin.
  • the drug is any suitable drug for treating epilepsy, for example, but not limited to, carbamazepine, phenytoin, and valproic acid.
  • Th selection of drug depends on the type of biometric signal and its associated disease or condition, and therefore the invention is not limited to any particular type of drug.
  • the invention also provides a pharmaceutical composition comprising compounds of the invention and one or more pharmaceutically acceptable carriers.
  • “Pharmaceutically acceptable carriers” include any excipient which is nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed.
  • the pharmaceutical composition may include one or additional therapeutic agents.
  • “Pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable carriers include solvents, dispersion media, buffers, coatings, antibacterial and antifungal agents, wetting agents, preservatives, chelating agents, antioxidants, isotonic agents and absorption delaying agents.
  • compositions of the present invention for treatment of conditions or diseases vary depending upon many different factors, including means of administration, target site, physiological state of the patient, other medications administered, and whether treatment is prophylactic or therapeutic.
  • the patient is a human but non- human mammals including transgenic mammals can also be treated.
  • Treatment dosages may be titrated using routine methods known to those of skill in the art to optimize safety and efficacy.
  • the dose of a given inhaled medication will generally depend on transpulmonary capillary uptake of medication and a patient’s body weight. However, given the direct transport of pulmonary blood and the administered drug to the left heart there will be no initial first pass pharmaceutical metabolism or drug tissue space redistribution. Thus, without being bound by theory, it is anticipated doses of medications needed for the treatment of cardiac arrhythmias will be substantially lower than the doses needed for the intravenous treatment of that same arrhythmia for any given agent. As an example, 5-10mg of Verapamil intravenously will typically terminate reentrant SVTs, however when inhaled it is anticipated under 1 mg of inhaled Verapamil should prove effective for this same arrhythmia.
  • Biometric reader described herein can be any suitable reader, known to one of skilled in the art, and such reader can be capable of detecting a biometric signal.
  • the biometric reader is an electrocardiogram (ECG).
  • ECG electrocardiogram
  • EEG electroencephalogram
  • the invention provides a method for manufacturing the device of the invention described herein.
  • the invention provides a method for treating an abnormal brain or body condition, such as a heart disease or a heart condition, or epilepsy in a subject, the method comprising: providing a device of the invention described herein, activating the device to detect the abnormal condition and delivering an inhalable drug to the subject.
  • an abnormal brain or body condition such as a heart disease or a heart condition, or epilepsy
  • the device of the invention can be used to treat any abnormal brain or body condition, such as a heart disease or a heart condition, which has an abnormal biometric signal, such as an electrical signal representing an abnormal heart rhythm.
  • a heart disease or condition includes, for example, but not limited to, a supraventricular tachycardia (SVT), an atrial flutter, and an atrial fibrillation.
  • Additional examples of a heart disease or condition includes, for example, but not limited to, a fast arrhythmia, a slow arrhythmia, a premature atrial contraction, a premature ventricular contraction, a paroxymal supraventricular tachycardia (PS VT), an accessory pathway tachycardia, AV nodal reentrant tachycardia, a ventricular tachycardia (V-tach), a ventricular fibrillation, a long QT syndrome, a bradyarrhythmia, a coronary artery disease, a heart valve disorder, and a heart failure.
  • PS VT paroxymal supraventricular tachycardia
  • V-tach ventricular tachycardia
  • V-tach ventricular tachycardia
  • the device of the invention can be used to treat an abnormal condition associated with epilepsy.
  • the invention provides a healthcare system comprising the device of the invention described herein.
  • the terms“plurality” and“a plurality” as used herein may include, for example,“multiple” or“two or more”.
  • the terms“plurality” or“a plurality” may be used throughout the specification to describe two or more components, devices, elements, units, parameters, or the like.
  • the term set when used herein may include one or more items.
  • the method embodiments described herein are not constrained to a particular order or sequence. Additionally, some of the described method embodiments or elements thereof can occur or be performed simultaneously, at the same point in time, or concurrently..

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Management (AREA)
  • Nursing (AREA)
  • Otolaryngology (AREA)
  • Critical Care (AREA)
  • Business, Economics & Management (AREA)

Abstract

L'invention concerne un inhalateur intelligent à commande biométrique et des méthodes associées. En particulier, l'invention concerne un dispositif comprenant un lecteur biométrique et une unité d'inhalateur pour détecter et traiter des états anormaux du cerveau et du corps.
PCT/US2020/037242 2019-06-11 2020-06-11 Inhalateurs intelligents à commande biométrique Ceased WO2020252169A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860048P 2019-06-11 2019-06-11
US62/860,048 2019-06-11

Publications (1)

Publication Number Publication Date
WO2020252169A1 true WO2020252169A1 (fr) 2020-12-17

Family

ID=73780845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/037242 Ceased WO2020252169A1 (fr) 2019-06-11 2020-06-11 Inhalateurs intelligents à commande biométrique

Country Status (1)

Country Link
WO (1) WO2020252169A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022172057A1 (fr) * 2021-02-11 2022-08-18 Mozafari Mojgan Inhalateur nanoin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106935A1 (en) * 2014-10-17 2016-04-21 Qualcomm Incorporated Breathprint sensor systems, smart inhalers and methods for personal identification
US20170249433A1 (en) * 2014-10-25 2017-08-31 Sumner Bluffs, Llc. Pharmaceutical and biological agent delivery system having biometric data acquisition and monitoring capabilities
US10058661B2 (en) * 2014-12-04 2018-08-28 Norton (Waterford) Limited Inhalation monitoring system and method
US20180279918A1 (en) * 2014-10-25 2018-10-04 Sumner Bluffs, Llc. Nebulizing devices and systems having biometric data acquisition and monitoring capabilities

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106935A1 (en) * 2014-10-17 2016-04-21 Qualcomm Incorporated Breathprint sensor systems, smart inhalers and methods for personal identification
US20170249433A1 (en) * 2014-10-25 2017-08-31 Sumner Bluffs, Llc. Pharmaceutical and biological agent delivery system having biometric data acquisition and monitoring capabilities
US20180279918A1 (en) * 2014-10-25 2018-10-04 Sumner Bluffs, Llc. Nebulizing devices and systems having biometric data acquisition and monitoring capabilities
US10058661B2 (en) * 2014-12-04 2018-08-28 Norton (Waterford) Limited Inhalation monitoring system and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022172057A1 (fr) * 2021-02-11 2022-08-18 Mozafari Mojgan Inhalateur nanoin

Similar Documents

Publication Publication Date Title
AU2022241504B2 (en) Methods of administering high concentrations of nitric oxide
Vakkuri et al. Spectral entropy monitoring is associated with reduced propofol use and faster emergence in propofol–nitrous oxide–alfentanil anesthesia
AU2018394928B2 (en) Use of inhaled nitric oxide and oxygen for the treatment of pulmonary hypertension
TWI572377B (zh) 用藥記錄裝置及其方法
US20160007913A1 (en) System for monitoring a state of disease
US20100189778A1 (en) Opioid delivery system
WO2006048417A1 (fr) Systeme et appareil de suivi de l'observance d'une therapie respiratoire
Neder et al. Effects of formoterol on exercise tolerance in severely disabled patients with COPD
US20130239962A1 (en) Methods Of Administering High Concentrations Of Nitric Oxide
Tobin et al. Astemizole-induced cardiac conduction disturbances in a child
Bartfield et al. Nebulized fentanyl for relief of abdominal pain
WO2020252169A1 (fr) Inhalateurs intelligents à commande biométrique
RU2015145450A (ru) Способы дистанционного контроля самостоятельного введения ваноксерина для прекращения острых эпизодов аритмии сердца у млекопитающих
Haji et al. Effects of a κ-receptor agonist U-50488 on bulbar respiratory neurons and its antagonistic action against the μ receptor-induced respiratory depression in decerebrate cats
US20240285858A1 (en) Medicament Delivery System
CA2556629A1 (fr) Systeme d'administration d'opioides
JP3148671U (ja) 吸入器
Schreck et al. Case studies illustrating the implementation of treatment strategies for acute and chronic asthma
WO2024249775A2 (fr) Méthodes de traitement de l'hypertension pulmonaire
McKenzie Drugs used to control asthma
US20040228808A1 (en) Opioid delivery system
JP2007525528A (ja) オピオイド送達系
Vale β2-agonists
Bateman Benzodiazepines
JP2003325666A (ja) エアロゾルを管理するための装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20821645

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20821645

Country of ref document: EP

Kind code of ref document: A1